title: Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy.
abstract: BACKGROUND
  A disintegrin and metalloproteinase (ADAM) 17 has been indicated to be an indispensable regulator of cellular events from proliferation to migration. Although prognostic importance of ADAM17 expression has been investigated in several tumours, its clinical utility as a useful prognostic molecular marker remains unclear in gastric cancer. In the current study, we evaluated the expression of ADAM17 and its prognostic significance in gastric cancer patients after curative gastrectomy.
  
  
  METHODS
  The prognostic significance of ADAM17 expression was analysed immunohistochemically in 156 patients with gastric cancer who had undergone curative gastrectomy, and the relationship between its expression and clinicopathological factors was also evaluated.
  
  
  RESULTS
  High ADAM17 expression was detected in 79 patients (51 %), whereas low expression was found in 77 cases (49 %). There was significant correlation between gender, histology, lymph node metastasis, vascular invasion, the presence of recurrence and high ADAM17 expression. Recurrence in patients with high ADAM17 expression was significantly higher than that for patients with low ADAM17 expression (p = 0.032). The median disease-free survival (DFS) time for patients with tumours with high ADAM17 expression was worse than that of patients with tumours with low ADAM17 expression (16.6 vs. 44.2 months, p = 0.004). In addition, patients with low ADAM17 expression had a higher median overall survival (OS) (49.6 vs. 26.9 months, p = 0.019) compared to those with high ADAM17 expression. Multivariate analysis indicated that the rate of ADAM17 expression was an independent prognostic factor for DFS, in addition to the already known important clinicopathological prognostic indicator. But the prognostic importance of ADAM17 expression could not be proved by multivariate analysis for OS.
  
  
  CONCLUSIONS
  The potential value of ADAM17 expression as a useful molecular marker in gastric cancer progression should be evaluated comprehensively; it may predict recurrence and poor prognosis in patients with gastric cancer after curative resection.
authors: Department of Medical Oncology, Dr. Lutfi Kırdar Kartal Education and Research Hospital, Istanbul, Turkey, dinceraydin79@yahoo.com.
authors: D
authors: D
authors: Aydin
authors: A
authors: A
authors: Bilici
authors: D
authors: D
authors: Yavuzer
authors: U
authors: U
authors: Kefeli
authors: A
authors: A
authors: Tan
authors: O
authors: O
authors: Ercelep
authors: A
authors: A
authors: Mert
authors: S
authors: S
authors: Yuksel
authors: M
authors: M
authors: Ozcelik
authors: D
authors: D
authors: Isik
authors: H
authors: H
authors: Surmeli
authors: H
authors: H
authors: Odabasi
authors: M
authors: M
authors: Aliustaoglu
mesh_terms: D051722:ADAM Proteins / Q000378:metabolism*; D000072198:ADAM17 Protein; D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D018279:Carcinoma, Signet Ring Cell / Q000378:metabolism / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy / Q000401:mortality*; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000378:metabolism / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D009367:Neoplasm Staging; D011379:Prognosis; D013274:Stomach Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D051722:ADAM Proteins; D000072198:ADAM17 Protein; C000606462:ADAM17 protein, human